Status:
COMPLETED
Improving Glycaemic Control in Patients With Type 2 Diabetes Mellitus Through Peer Support Instant Messaging
Lead Sponsor:
St. Pölten University of Applied Sciences
Collaborating Sponsors:
Karl Landsteiner University of Health Sciences
Austrian Health Insurance Fund
Conditions:
Diabetes Mellitus, Type 2
Peer Support
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
Diabetes mellitus is one of the four priority non-communicable diseases worldwide. Globally, 425 million adults suffered from diabetes mellitus (7.2-11.3%) in 2017 and the International Diabetes Feder...
Eligibility Criteria
Inclusion
- Inclusion criteria participants exclusive moderators:
- diagnosed type 2 diabetes mellitus according to the Austrian definition
- HbA1c of ≥ 6.5% (48 mmol/mol) at the last measurement
- receive the antidiabetic therapy according to the current guidelines
- older than 40 years
- living in Lower Austria
- get oral hyperglycaemic agents for maximum three years
- understand the individual commitments during trial
- must be able to visit training and measurements
- Inclusion criteria moderators:
- diagnosed type 2 diabetes mellitus according to the Austrian definition
- HbA1c of ≥ 6.5% (48 mmol/mol) at the last measurement
- receive the antidiabetic therapy according to the current guidelines
- get oral hyperglycaemic agents for three years minimum
- older than 60 years
- living in the vicinity of the training location in St. Pölten, which means residing in St. Pölten, St. Pölten Land, Melk, Krems, or Lilienfeld
- engaged participating (= regular participation) in the Austrian disease management program 'Therapie aktiv - Diabetes im Griff'
- understand the individual commitments during trial
- must be able to visit training and measurements
- commitment to undergo the moderator training
- Exclusion Criteria for all participants:
- hospitalization of more than 3 weeks during the intervention
- eye disorders that severely limit vision and, hence, inability to read the display (e.g., proliferative retinopathy or macular edema)
- severe illnesses such as kidney, liver, heart disease, or malignant cancer, neurological of mental illness which make a longer hospitalization likely
- substance abuse
- pregnancy
- limitation in the German language
- unable to visit training and measurements
Exclusion
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2025
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04797429
Start Date
November 1 2020
End Date
March 1 2025
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sankt Pölten University of Applied Sciences
Sankt Pölten, Lower Austria, Austria, 3100